Study protocol 2: impacts of overnight 1 mg dexamethasone on vascular function in patients with NFA
adrenal incidentalomas, Cushing’s syndrome
PRIMARY ALDOSTERONISM, ADRENAL INCIDENTALOMA
Between November 2020 and August 2022, a total of 28 consecutive patients with adrenal incidentalomas were recruited for vascular function measurements from patients who attended the outpatient clinic at Hiroshima University Hospital. Ten of the 28 patients with adrenal incidentalomas, including five patients with subclinical Cushing’s syndrome three patients with Cushing’s syndrome, and two patients with primary aldosteronism, were excluded. Finally, 18 patients with NFA were enrolled in this study. FMD and NID were measured in the morning before and after administration of 1 mg of dexamethasone at 2300 h as a dexamethasone suppression test for all patients.